1,581 results on '"Nakanishi, Yoichi"'
Search Results
2. Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers
3. Future challenges and their impact on respiratory health and lung cancer
4. Prognosis and management of chronic obstructive pulmonary disease in a real-world setting: A 5-year follow-up analysis of a multi-institutional registry
5. A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
6. Nab-Paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment
7. Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC
8. Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib
9. Lung Cancer in the Elderly: The Most Dominant Cause of Cancer Death in Japan
10. Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy
11. Incense smoke-induced oxidative stress disrupts tight junctions and bronchial epithelial barrier integrity and induces airway hyperresponsiveness in mouse lungs
12. Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events
13. Risk factors for disease progression in Japanese patients with COVID-19 with no or mild symptoms on admission
14. Characteristics of tobacco-related lung diseases in Fukuoka Prefecture, Japan: A prospective, multi-institutional, observational study
15. Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry
16. World Lung Day 2023—Access to prevention and treatment for all, leave no one behind
17. Five-year follow up analysis of Japanese ILD registry
18. Safety and efficacy of brilliant blue g250 (BBG) for lens capsular staining: a phase III physician-initiated multicenter clinical trial
19. Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors
20. Preclinical Toxicity Studies for Regenerative Medicine in Japan
21. Anticancer drug treatment for advanced lung cancer with interstitial lung disease
22. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers
23. Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
24. Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients
25. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma
26. A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L
27. Data from TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells
28. ntary Methods, Figure Legends from TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells
29. Supplementary Figures 1 - 7 from TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells
30. Supplementary Figure S1 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
31. Supplementary Table S1 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
32. Supplementary Figure 5 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma
33. Data from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma
34. Supplementary Figure 2 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma
35. Supplementary Figure 1 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma
36. Supplementary Figure 3 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma
37. Supplementary Figure 4 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma
38. Supplementary Figure Legends 1-5 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma
39. Effects of cigarette smoke on barrier function and tight junction proteins in the bronchial epithelium: protective role of cathelicidin LL-37
40. 18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer
41. Lung Cancer in the Elderly: The Most Dominant Cause of Cancer Death in Japan
42. Molecular Cloning of Vacuolar H⁺-Pyrophosphatase and Its Developmental Expression in Growing Hypocotyl of Mung Bean
43. Effects of treatment with corticosteroids on human rhinovirus-induced asthma exacerbations in pediatric inpatients: a prospective observational study
44. Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer
45. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors
46. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial
47. Periodontal status and lung function decline in the community: the Hisayama study
48. Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non–small-cell lung cancer
49. Prevalence of asthma with airflow limitation, COPD, and COPD with variable airflow limitation in older subjects in a general Japanese population: The Hisayama Study
50. Validation of a COPD screening questionnaire and establishment of diagnostic cut-points in a Japanese general population: The Hisayama study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.